DE69928763D1 - Adjuvanzien zur Verwendung in Impfstoffen - Google Patents

Adjuvanzien zur Verwendung in Impfstoffen

Info

Publication number
DE69928763D1
DE69928763D1 DE69928763T DE69928763T DE69928763D1 DE 69928763 D1 DE69928763 D1 DE 69928763D1 DE 69928763 T DE69928763 T DE 69928763T DE 69928763 T DE69928763 T DE 69928763T DE 69928763 D1 DE69928763 D1 DE 69928763D1
Authority
DE
Germany
Prior art keywords
vaccines
adjuvants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928763T
Other languages
English (en)
Other versions
DE69928763T2 (de
Inventor
Don Alan Dearwester
Leroy Allen Swearingin
David Stewart Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE69928763D1 publication Critical patent/DE69928763D1/de
Publication of DE69928763T2 publication Critical patent/DE69928763T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE69928763T 1999-01-29 1999-12-23 Adjuvanzien zur Verwendung in Impfstoffen Expired - Lifetime DE69928763T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11770599P 1999-01-29 1999-01-29
US117705P 1999-01-29
US12176099P 1999-02-26 1999-02-26
US121760P 1999-02-26

Publications (2)

Publication Number Publication Date
DE69928763D1 true DE69928763D1 (de) 2006-01-12
DE69928763T2 DE69928763T2 (de) 2006-06-29

Family

ID=26815550

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928763T Expired - Lifetime DE69928763T2 (de) 1999-01-29 1999-12-23 Adjuvanzien zur Verwendung in Impfstoffen

Country Status (17)

Country Link
US (6) US6572861B1 (de)
EP (2) EP1616573B1 (de)
JP (3) JP2000219636A (de)
CN (2) CN1126568C (de)
AR (2) AR035474A1 (de)
AT (2) ATE311900T1 (de)
AU (2) AU769539B2 (de)
BR (2) BRPI0000126B8 (de)
CA (2) CA2296244C (de)
CY (2) CY1105684T1 (de)
DE (1) DE69928763T2 (de)
DK (2) DK1616573T3 (de)
ES (2) ES2251164T3 (de)
HK (2) HK1030166A1 (de)
NZ (2) NZ502341A (de)
PT (1) PT1616573E (de)
TW (1) TW585777B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US7279163B1 (en) * 2002-03-21 2007-10-09 The United States Of America, As Represented By The Secretary Of Agriculture Water-in-oil emulsion vaccines
BR0313806A (pt) * 2002-08-26 2005-07-05 Pfizer Prod Inc Vacinas para infecções nos sistemas respiratório e reprodutor em gado
EP1592444B1 (de) * 2003-01-29 2008-05-14 Pfizer Products Inc. Hundeimpfstoffe gegen bordetella bronchiseptica
PL1613346T3 (pl) * 2003-04-04 2013-03-29 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie i kompozycje szczepionek
US8637047B2 (en) * 2003-10-30 2014-01-28 Boehringer Ingelheim Vetmedica, Inc. Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same
CN1323718C (zh) * 2004-03-15 2007-07-04 中国农业科学院兰州兽医研究所 一种利用植物油佐剂制备动物病毒性、细菌性疫苗的方法
FR2878746B1 (fr) * 2004-12-02 2007-02-23 Vetoquinol Sa Sa Nouvelle composition pharmaceutique utilisable dans le domaine des vaccins
CN1320924C (zh) * 2005-01-07 2007-06-13 邢为藩 一种自乳化疫苗佐剂及其制备方法
EP2368569A3 (de) 2006-01-18 2012-05-02 University Of Chicago Zusammensetzungen und Verfahren im Zusammenhang mit Proteinen des Staphylococcus-Bakteriums
PT2068918E (pt) 2006-09-26 2012-08-06 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2668417A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
KR101333852B1 (ko) 2008-06-27 2013-11-27 조에티스 엘엘씨 신규한 면역증강 조성물
AU2009302582A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
WO2011005341A2 (en) 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
EP2437753B1 (de) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen die diese enthalten
US9849174B2 (en) 2009-11-20 2017-12-26 The Board Of Regents Of The University Of Texas System Methods and compositions related to immunogenic fibrils
WO2011063264A1 (en) 2009-11-20 2011-05-26 University Of Chicago Methods and compositions related to immunogenic fibrils
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2011112871A1 (en) 2010-03-11 2011-09-15 Immune Design Corp. Vaccines for pandemic influenza
AU2011247359A1 (en) 2010-04-30 2012-11-15 Telormedix Sa Methods for inducing an immune response
WO2011134668A1 (en) 2010-04-30 2011-11-03 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
WO2012003474A2 (en) 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
WO2012042857A1 (ja) * 2010-09-28 2012-04-05 共立製薬株式会社 粘膜アジュバント組成物
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012149307A2 (en) 2011-04-27 2012-11-01 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CN103998058B (zh) 2011-10-06 2021-11-05 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
GB201205237D0 (en) 2012-03-26 2012-05-09 Univ Edinburgh Adjuvant
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
BR112014028476A2 (pt) 2012-05-16 2017-08-01 Immune Design Corp fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
WO2014039978A2 (en) 2012-09-10 2014-03-13 Szathmary Dr Susan Vaccine to prevent mycoplasmal infection in waterfowl
EP2903987B1 (de) 2012-10-01 2017-09-20 Urogen Pharma Ltd. Phospholipid-wirkstoffanaloga
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
LT3166634T (lt) 2014-07-11 2021-11-10 Zoetis Services Llc Naujos vakcinos kompozicijos prieš kiaulių epideminės diarėjos virusą
AU2016225119B2 (en) 2015-02-27 2021-06-03 Iowa State University Research Foundation, Inc. Porcine Epidemic Diarrhea Virus strains and immunogenic compositions therefrom
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
BR112018069371A2 (pt) 2016-03-21 2019-01-22 South Dakota Board Of Regents construção de ácido nucleico, vetor, vacina ou composição imunogênica, método de entrega de uma vacina, método de produção de uma construção de ácido nucleico e método para conferir imunidade contra um antígeno
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN107027749B (zh) * 2017-05-24 2021-04-09 浙江工业大学 一种复合乳化剂及其在复配毒死蜱农药中的应用
ES2705378A1 (es) * 2017-09-22 2019-03-22 Decco Worldwide Post Harvest Holdings B V Metodo para el tratamiento y control de fisiopatias de postcosecha de frutas mediante recubrimientos comestibles.
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
EP3843782A1 (de) 2018-08-29 2021-07-07 Centre Hospitalier Universitaire Vaudois (CHUV) Ebolaimpfstoffzusammensetzungen und verfahren zu ihrer verwendung
US11208167B2 (en) 2018-11-15 2021-12-28 Kuat Innovations Llc Bicycle rack with actuated arm
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
CN113907044A (zh) * 2021-11-09 2022-01-11 福建省连江县刘氏兔业养殖场 一种抗病猪品系的培育方法及其应用
WO2023111907A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070454A (en) * 1973-05-04 1978-01-24 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
AT350181B (de) * 1977-05-04 1979-05-10 Schuller Walter Dr Verfahren zur herstellung einer mischvaccine
US4137115A (en) * 1977-11-07 1979-01-30 Patrick Lambert Joining structure
US4237115A (en) * 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4261925A (en) 1978-04-05 1981-04-14 The Dow Chemical Company Surfactants
US4504275A (en) 1983-03-24 1985-03-12 Imperial Chemical Industries Plc Emulsifying agents
US4933179A (en) 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5338748A (en) 1985-01-18 1994-08-16 Cetylite Industries, Inc. Sterilant composition
US5424323A (en) * 1985-01-18 1995-06-13 Cetylite Industries, Inc. Sterilant composition
DE3517805A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Impfstoff zur immunisierung von schweinen gegen rhinitis atrophicans (schnueffelkrankheit)
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US5019388A (en) 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4888169A (en) 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5209929A (en) * 1987-03-19 1993-05-11 Washington State University Research Foundation Immunization against Babesiosis using purified merozoite surface antigens of Basesia bigemina
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5069901A (en) * 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5223253A (en) * 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
JP3035712B2 (ja) * 1990-02-12 2000-04-24 スミスクライン ビーチャム バイオロジカルズ（エス ア） 新規なワクチンおよびそのための方法
AU657907B2 (en) * 1990-05-29 1995-03-30 Wyeth Holdings Corporation Mycoplasma hyopneumoniae vaccine
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
ES2136064T3 (es) * 1990-06-13 1999-11-16 Pfizer Vacunas de toxoide de pasteurella multocida.
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
WO1993010216A1 (en) 1991-11-15 1993-05-27 Smithkline Beecham Corporation Gram-negative bacterial vaccines
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
DE4222153C2 (de) 1992-07-06 1998-12-03 Peter Siegfried Verfahren zur Entölung von Rohlecithin
DK0626452T3 (da) * 1993-05-17 2000-02-14 Akzo Nobel Nv Vaccine mod infektion af Streptococcus suis
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
AU679845B2 (en) * 1994-02-18 1997-07-10 Solidose L.L.C. Inoculation of animals with dried, pelleted biological materials
DK53595A (da) * 1994-05-13 1995-11-14 Iberica Cyanamid Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner
ATE248603T1 (de) * 1994-06-10 2003-09-15 Chemo Sero Therapeut Res Inst Reinigungsverfahren für von bordetella produziertem nekrotoxin
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5625038A (en) * 1994-07-27 1997-04-29 Henderson; Louise M. Monoclonal antibodies specific for Erysipelothrix rhusiopathiae
US5603951A (en) 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US5814321A (en) 1995-11-30 1998-09-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
DK0835930T3 (da) 1996-10-09 2001-06-18 Akzo Nobel Nv Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV)
ZA982870B (en) * 1997-04-10 1998-10-09 Akzo Nobel Nv Live attenuated bacteria of the species actinobacillus pleuropneumoniae
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae

Also Published As

Publication number Publication date
CA2296244C (en) 2004-04-27
CN1126568C (zh) 2003-11-05
PT1616573E (pt) 2012-01-11
EP1616573A2 (de) 2006-01-18
EP1023904A3 (de) 2002-08-21
ATE533504T1 (de) 2011-12-15
JP4785365B2 (ja) 2011-10-05
CA2296244A1 (en) 2000-07-29
US20030175309A1 (en) 2003-09-18
US7393535B2 (en) 2008-07-01
CY1105684T1 (el) 2010-12-22
US20050058667A1 (en) 2005-03-17
CN1270838A (zh) 2000-10-25
JP2005041883A (ja) 2005-02-17
US20030175298A1 (en) 2003-09-18
TW585777B (en) 2004-05-01
CY1112521T1 (el) 2015-12-09
JP2000219636A (ja) 2000-08-08
US6814971B2 (en) 2004-11-09
EP1616573B1 (de) 2011-11-16
ATE311900T1 (de) 2005-12-15
US6572861B1 (en) 2003-06-03
DE69928763T2 (de) 2006-06-29
EP1023904B1 (de) 2005-12-07
ES2374628T3 (es) 2012-02-20
US20030175299A1 (en) 2003-09-18
HK1059739A1 (en) 2004-07-16
NZ502341A (en) 2001-08-31
CN1449825A (zh) 2003-10-22
US6733754B2 (en) 2004-05-11
AR035474A1 (es) 2004-06-02
CA2455134A1 (en) 2000-07-29
AU2004201021A1 (en) 2004-04-08
JP5167469B2 (ja) 2013-03-21
BRPI0017566B1 (pt) 2015-11-10
BRPI0000126B1 (pt) 2015-07-14
DK1616573T3 (da) 2012-01-30
NZ513202A (en) 2003-02-28
ES2251164T3 (es) 2006-04-16
BR0000126A (pt) 2001-05-02
US20030175308A1 (en) 2003-09-18
CN1449825B (zh) 2012-08-22
EP1616573A3 (de) 2007-05-09
CA2455134C (en) 2010-05-11
EP1023904A2 (de) 2000-08-02
HK1030166A1 (en) 2001-04-27
DK1023904T3 (da) 2005-12-27
BRPI0000126B8 (pt) 2022-05-10
AR055422A2 (es) 2007-08-22
AU6537299A (en) 2000-08-03
JP2004002479A (ja) 2004-01-08
AU769539B2 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
DE69928763D1 (de) Adjuvanzien zur Verwendung in Impfstoffen
DK1163000T3 (da) Vacciner imod antigener fra bakterier
NO20021433D0 (no) Vaksiner
NO20031483D0 (no) Vaksine
DE60127333D1 (de) Wirbelsäulenimplantat
FR2803504B1 (fr) Oreiller anatomique
DE50010727D1 (de) Flächiges Implantat
DE60143301D1 (de) Polyarylcarboxamide zur verwendung als lipidsenker
DE60015879D1 (de) Wirbelsäulenimplantat
ATE490327T1 (de) Impfstoffzusammensetzung
NO20025578D0 (no) Medisinsk innretning
NO20024172D0 (no) Vaksine
FR2815535B1 (fr) Implant pediculaire
DE50111900D1 (de) Medizinisches implantat
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20020763L (no) Vaksine
FR2806309B1 (fr) Implant
CU23064A3 (es) Conjunto implante dental-transportador
IS5999A (is) Beinvaxtarörvandi þáttur
DE50113937D1 (de) System zur datenübermittlung
NO20030497D0 (no) Innretning med kunstige luftveier
HK1045701A1 (zh) Fima菌毛基疫苗
AU2003204726A1 (en) Adjuvants for Use in Vaccines
ZA200000142B (en) Adjuvants for use in vaccines.
NO20002213L (no) Babesia vaksine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition